Claims for Patent: 5,356,804

Summary for Patent: 5,356,804

Title:	Cloning and expression of biologically active human .alpha.-galactosidase A
Abstract:	The present invention involves the production of large quantities of human .alpha.-Gal A by cloning and expressing the .alpha.-Gal A coding sequence in eukaryotic host cell expression systems. The eukaryotic expression systems, and in particular the mammalian host cell expression system described herein provide for the appropriate cotranslational and posttranslational modifications required for proper processing, e.g., glycosylation, phosphorylation, etc. and sorting of the expression product so that an glycosylation, phosphorylation, etc. and sorting of the expression product so that an active enzyme is produced. In addition, the expression of fusion proteins which simplify purification is described. Using the methods described herein, the recombinant .alpha.-Gal A is secreted by the engineered host cells so that it is recovered from the culture medium in good yield. The .alpha.-Gal A produced in accordance with the invention may be used in the treatment in Fabry Disease; for the hydrolysis of .alpha.-galactosyl residues in glycoconjugates; and/or for the conversion of the blood group B antigen on erythrocytes to the blood group O antigen.
Inventor(s):	Desnick; Robert J. (New York, NY), Bishop; David F. (New York, NY), Ioannou; Yiannis A. (New York, NY)
Assignee:	Mount Sinai School of Medicine of the City of New York (New York, NY)
Application Number:	07/602,824
Patent Claims:	1. A method for producing human .alpha.-galactosidase A comprising: (a) culturing a mammalian cell containing a chromosomally integrated nucleotide sequence encoding human .alpha.-galactosidase A controlled by a regulatory sequence that promotes gene expression and a selectable marker controlled by the same or different regulatory sequence, so that the .alpha.-galactosidase A nucleotide sequence is stably overexpressed and an enzymatically active .alpha.-galactosidase A enzyme is secreted by the mammalian cell; and (b) isolating enzymatically active .alpha.-galactosidase A enzyme from the mammalian cell culture. 2. The method according to claim 1 wherein, in the presence of selection, the chromosomally integrated nucleotide sequences are amplified. 3. The method according to claim 1 in which the nucleotide sequence encoding human .alpha.-galactosidase A encodes the amino acid sequence depicted in FIGS. 1A-1C [SEQ ID No: 2] from amino acid residue number 1 to 430. 4. The method according to claim 1 in which the nucleotide sequence encoding human .alpha.-galactosidase A encodes the amino acid sequence depicted in FIGS. 1A-1C [SEQ. ID No. 1] from amino acid[residue number 31 to 430. 5. The method according to claim 1 in which the regulatory sequence that promotes gene expression is a viral promoter. 6. The method according to claim 1 in which the regulatory sequence that promotes gene expression is an inducible promoter. 7. The method according to claim 1 in which the selectable marker is dihydrofolate reductase. 8. The method according to claim 2 in which the selectable marker is dihydrofolate reductase and the selection is methotrexate. 9. The method according to claim 1 in which the mammalian cell is a Chinese hamster ovary cell line. 10. A mammalian cell comprising a chromosomally integrated nucleotide sequence encoding human .alpha.-galactosidase A controlled by a regulatory sequence that promotes gene expression and a selectable marker controlled by the same or different regulatory sequence, so that the .alpha.-galactosidase A nucleotide sequence is stably overexpressed and an enzymatically active .alpha.-galactosidase A enzyme is secreted by the mammalian cell. 11. The mammalian cell of claim 10 wherein the chromosomally integrated nucleotide sequences are amplified. 12. The mammalian cell according to claim 10 in which the nucleotide sequence encoding human .alpha.-galactosidase A encodes the amino acid sequence depicted in FIGS. 1A-1C [SEQ. ID. No. 2] from amino acid residue number 1 to 430. 13. The mammalian cell according to claim 10 in which the nucleotide sequence encoding human .alpha.-galactosidase A encodes the amino acid sequence depicted in FIG. 1A [SEQ. ID No: 1] from amino acid residue number 31 to 430. 14. The mammalian cell according to claim 10 in which the regulatory sequence that promotes gene expression is a viral promoter. 15. The mammalian cell according to claim 10 in which the regulatory sequence that promotes gene expression is an inducible promoter. 16. The mammalian cell according to claim 10 in which the selectable marker is dihydrofolate reductase. 17. The mammalian cell according to claim 10 in which the mammalian cell is a Chinese hamster ovary cell line.

Details for Patent 5,356,804

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genzyme Corporation	FABRAZYME	agalsidase beta	For Injection	103979	04/24/2003		2039-02-26
Genzyme Corporation	FABRAZYME	agalsidase beta	For Injection	103979	10/10/2003		2039-02-26

International Patent Family for US Patent 5,356,804

Country	Patent Number	Estimated Expiration
Austria	213020
Austria	241010
Austria	464386